Fr. 89.00

Atlas of Rheumatoid Arthritis

English · Paperback / Softback

Shipping usually within 1 to 2 weeks (title will be printed to order)

Description

Read more

Atlas of Rheumatoid Arthritis is a high-quality educational initiative, written by leaders in the field of rheumatology, containing a collection of approximately 150 relevant images, with extended descriptive captions and a comprehensive bibliography.

The Atlas of Rheumatoid Arthritis will provide clinicians with a visual guide to rheumatoid arthritis, focusing on assessment, diagnosis and treatment, including newer research into the signalling pathways involved in the pathogenesis of RA, before focusing on the treatment of RA.

Rheumatoid arthritis (RA) is the most common and most serious of the inflammatory arthritic disorders, and it dominates clinical rheumatological practice. Effective, early treatment is vital as this can slow the course of the disease and reduce joint damage. RA is usually treated using disease-modifying anti-rheumatic drugs (DMARDs), most commonly methotrexate. The newest treatments target the disease-causing immune elements specifically and directly.

List of contents

Classification of rheumatoid arthritis.- Pre-rheumatoid arthritis.- Early rheumatoid arthritis.- Established rheumatoid arthritis.- Remission and rheumatoid arthritis.- Magnetic resonance imaging in rheumatoid arthritis.- Ultrasound imaging in rheumatoid arthritis.- Dual energy X-ray absorptiometry in rheumatoid arthritis.- Methotrexate.- Immunotherapy.- Rituximab.- Novel therapies in rheumatoid arthritis: small molecules.

About the author

Professor Paul Emery is the Arthritis Research UK Professor of Rheumatology and Director ofthe Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the Leeds
Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, United
Kingdom. Professor Emery was the President of the European League Against Rheumatism
(EULAR) from 2009–2011 and has served on the editorial boards major rheumatology journals
including Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinical
and Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President of
International Extremity MRI Society (ISEMIR) and is a National Institute for Health Research
(NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award for
Clinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULAR
Prize for outstanding contribution to rheumatology research; and the Carol Nachman Prize
for outstanding rheumatology research. Professor Emery’s research interests center around the
immunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connective
tissue diseases. He has a special interest in the factors leading to persistent inflammation
and has published over 950 peer-reviewed articles in this area.

is the Arthritis Research UK Professor of Rheumatology and Directorofthe Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the Leeds
Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, United
Kingdom. Professor Emery was the President of the European League Against Rheumatism
(EULAR) from 2009–2011 and has served on the editorial boards major rheumatology journals
including Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinical
and Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President of
International Extremity MRI Society (ISEMIR) and is a National Institute for Health Research
(NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award for
Clinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULAR
Prize for outstanding contribution to rheumatology research; and the Carol Nachman Prize
for outstanding rheumatology research. Professor Emery’s research interests center around the
immunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connective
tissue diseases. He has a special interest in the factors leading to persistent inflammation
and has published over 950 peer-reviewed articles in this area.

Summary

Atlas of Rheumatoid Arthritis is a high-quality educational initiative, written by leaders in the field of rheumatology, containing a collection of approximately 150 relevant images, with extended descriptive captions and a comprehensive bibliography. The Atlas of Rheumatoid Arthritis will provide clinicians with a visual guide to rheumatoid arthritis, focusing on assessment, diagnosis and treatment, including newer research into the signalling pathways involved in the pathogenesis of RA, before focusing on the treatment of RA. Rheumatoid arthritis (RA) is the most common and most serious of the inflammatory arthritic disorders, and it dominates clinical rheumatological practice. Effective, early treatment is vital as this can slow the course of the disease and reduce joint damage. RA is usually treated using disease-modifying anti-rheumatic drugs (DMARDs), most commonly methotrexate. The newest treatments target the disease-causing immune elements specifically and directly.

Product details

Authors Paul Emery
Assisted by Pau Emery (Editor), Paul Emery (Editor)
Publisher Springer, Berlin
 
Languages English
Product format Paperback / Softback
Released 01.01.2015
 
EAN 9781907673900
ISBN 978-1-907673-90-0
No. of pages 264
Dimensions 142 mm x 17 mm x 213 mm
Weight 382 g
Illustrations XI, 264 p. 166 illus., 115 illus. in color.
Series Springer Healthcare
Springer Healthcare
Subjects Natural sciences, medicine, IT, technology > Medicine > General
Non-fiction book > Dictionaries, reference works

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.